MAPS News - onset.to

October 5, 2026

maps.org · Oct 5, 2026

September 29, 2026

MAPS opposes the DEA's attempt to place five lesser-known tryptamines into Schedule I under the Controlled Substances Act

maps.org · Sep 29, 2026 · Ismail L. Ali, J.D.

Article Policy Research Safety

August 25, 2026

University of Miami’s Gift of Its 1994 Ibogaine IND to HHS Advances Open Science While Highlighting Modern Safety and Sourcing Needs

maps.org · Aug 25, 2026

Ibogaine Article Ethics Research Safety

August 10, 2026

MAPS addresses progress in FDA discussions on MDMA-assisted therapy for PTSD and outlines regulatory steps, safety oversight, and the path toward potential resubmission

maps.org · Aug 10, 2026

MDMA Clinical Policy Therapy

July 31, 2026

MAPS finalizes agreement with the University of Alabama at Birmingham for an inhaled cannabis PTSD clinical trial in veterans

maps.org · Jul 31, 2026

Cannabis Article Clinical Research Society

July 20, 2026

Clinical-Trial Cannabis and Placebo Shipped to Support Canadian Clinical Research

maps.org · Jul 20, 2026

Cannabis Article Clinical Research

July 8, 2026

MAPS policy advocacy in the second quarter of 2026 centers federal and state psychedelic reform, coalition work, and public education across multiple jurisdictions

maps.org · Jul 8, 2026

Community Mainstream Policy

June 30, 2026

Ibogaine Investigator's Brochure outlines pharmacology, safety profile, and clinical development context for ibogaine in regulated research settings

maps.org · Jun 30, 2026

Ibogaine Clinical Research Safety

MAPS publishes a free open-access ibogaine Investigator's Brochure to support researchers with pharmacology, safety, dosing, and clinical development guidance

maps.org · Jun 30, 2026

Ibogaine Clinical Education Research

June 25, 2026

Psychedelic Science 2027 opens speaker submissions and calls on researchers, clinicians, policymakers, and community leaders to connect psychedelic promise with real-world practice

maps.org · Jun 25, 2026

Clinical Events Research

June 18, 2026

MAPS statement addresses the Supreme Court's ruling in United States v. Hemani and its implications for religious freedom, controlled substances, and psychedelic communities

maps.org · Jun 18, 2026

Community Ethics Policy

June 2, 2026

MAPS publishes a Psychedelic Science in Public Interest literature review on psychedelic research, ethics, policy, and public benefit

maps.org · Jun 2, 2026

Ethics Policy Research

May 14, 2026

Psychedelic Science 2027 opens early bird registration as MAPS confirms June 15-21 dates for its Denver gathering on science, medicine, policy, and culture

maps.org · May 14, 2026

Article Community Events Research

May 7, 2026

MAPS appoints Liana Gillooly and Andrew Mo Septimus to its Board of Directors, adding policy, philanthropy, and nonprofit leadership to psychedelic medicine governance

maps.org · May 7, 2026

Business Industry Mainstream

May 5, 2026

MAPS and the State of Colorado partner to deliver free harm reduction training for first responders amid the state's regulated psychedelic ecosystem

maps.org · May 5, 2026

HarmReduction Policy Safety

May 4, 2026

MAPS welcomes a bipartisan congressional letter urging the FDA to clarify and improve the regulatory path for psychedelic-assisted therapies

maps.org · May 4, 2026

Psilocybin MDMA Mainstream Policy Therapy

April 27, 2026

MAPS verlegt seinen Stammsitz von Kalifornien nach Colorado und verbindet den Umzug mit strategischer Neuausrichtung, Finanzierung und organisatorischem Wandel

maps.org · Apr 27, 2026

Business Community Industry

April 23, 2026

MAPS feiert 40 Jahre und fordert bei Psychedelika jetzt Fokus auf therapeutische Integrität und gerechten Zugang

maps.org · Apr 23, 2026 · Rick Doblin, Ph.D.; Betty Aldworth; Ismail Ali, J.D.

LSD Ayahuasca Ibogaine MDMA +2

April 18, 2026

MAPS begrüßt Bundesmaßnahmen zur Förderung evidenzbasierter Psychedelika-Forschung und -Politik (18. April 2026)

maps.org · Apr 18, 2026 · Betty Aldworth and Ismail L. Ali, J.D.

LSD Psilocybin Ibogaine MDMA

March 30, 2026

2026 First Quarter Legislative Wrap Up highlights state psychedelic policy bills across New York, Utah, Massachusetts, Washington, New Jersey, and Colorado

maps.org · Mar 30, 2026

Psilocybin Mescaline Policy Research +3

March 11, 2026

MAPS partners with the Shulgin Foundation on Music Is the Bridge video series featuring Reggie Watts and Hamilton Morris at the lab

maps.org · Mar 11, 2026 · Devon Phillips (Partnerships Manager, MAPS)

MDMA Culture Mainstream Music

March 9, 2026

MAPS Sends Expert Delegation to UN Commission on Narcotic Drugs for CND 69 in Vienna, March 9-13, 2026

maps.org · Mar 9, 2026

Community Policy Research

February 5, 2026

In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reform

maps.org · Feb 5, 2026

Psilocybin MDMA Community Policy Safety

February 3, 2026

MAPS und Columbia University starten eine Studie zu MDMA-unterstützter Paartherapie in der Praxis

maps.org · Feb 3, 2026 · Multidisciplinary Association for Psychedelic Studies (MAPS)

MDMA Policy Research Therapy

January 30, 2026

MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study

maps.org · Jan 30, 2026

Cannabis Article Clinical Policy Research